Views provided by UsageCounts
Table S1: Baseline characteristics – Bowel movements/day, BSFS types; Table S2: Changes in body weight and BMI; Table S3: GSRS dimensions during the study phases; Figure S1: Gastrointestinal adverse events after first intake with probable or possible connection to cellobiose intake.
Submitted 2019-12-24
Cellobiose; β(1→4) glycosidic bond; dose-escalation study; safety; tolerability; fermentable disaccharide; maximum tolerated dose; Bristol Stool Form Scale; Gastrointestinal Symptom Rating Scale; sugar replacer
Cellobiose; β(1→4) glycosidic bond; dose-escalation study; safety; tolerability; fermentable disaccharide; maximum tolerated dose; Bristol Stool Form Scale; Gastrointestinal Symptom Rating Scale; sugar replacer
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 3 |

Views provided by UsageCounts